-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Strengthening financing in the pharmaceutical industry will help to further optimize the layout of R&D pipelines, which is a beautiful landscape in the pharmaceutical fie.
Since the beginning of this year, the pharmaceutical industry has been setting off a wave of financing; for example, recently, a number of pharmaceutical companies have announced that they will raise or have completed hundreds of millions of financing, which will be used for new drug research and developme.
Kriya Completes $270 Million Series C Financing On May 17, Kriya Therapeutics announced the completion of a $270 million Series C financing round, which will be used to advance its R&D pipeline and further expand its engineering, manufacturing and computing platfor.
It is understood that the company's goal is to become a fully integrated gene therapy company, revolutionizing the design, development and manufacturing of gene therapy, increasing the speed to market and reducing cos.
At present, Kriya has actually built an ecosystem to develop potential "best-in-class" gene therapies, which consists of four core business units, namely technology, manufacturing, research and development, and treatme.
In addition, the company's computational engine, SIRVE, has also been able to integrate the vast amounts of data generated by the company's engineered and high-throughput screening platforms to support machine learning-enabled analysis and intelligent product desi.
Junshi Biology plans to raise 98 billion yuan for innovative drug research and developme.
On May 16, Junshi Biology submitted a prospectus for the issuance of A shares to specific objects in 202 The sponsor is Haitong Securiti.
According to the announcement, the number of shares issued this time does not exceed 70 million shar.
The total amount of funds raised in this issuance (including issuance expenses) shall not exceed RMB 980 billion (including this amoun.
Use raised funds of 6822 billion yuan), including JS001 (PD-1) follow-up domestic and overseas clinical research and development, JS004 (BTLA antibody) domestic and overseas Phase III clinical research and development, JS111 (EGFR exon20) domestic and overseas clinical research and development projects and other early stage projects preclinical studies .
In addition, Junshi Bio also plans to use the raised funds of 298 million yuan to establish a Shanghai headquarters and R&D center in the Shanghai International Medical Park in Shanghai Zhangjiang Science Ci.
Starna Therapeutics completes 150 million yuan in financing and is committed to developing mRNA therapy Recently, Starna Therapeutics announced the completion of 150 million yuan in Series A financi.
This round of financing was led by LYFE Capital (Zhouling Capital), Source Code Capital and Hony Capital And Chunhua Venture Capital followed the investment, Hillhouse Venture Capital and Sherpa Investment continued to increase their investme.
According to the data, Xingrui Medicine was founded in August 2021 and is committed to developing innovative mRNA drugs based on unmet clinical nee.
At present, it has established a technology platform for mRNA design synthesis and lipid nanoparticle (LNP) delivery, which is capable of achieving tissue-specific mRNA drug delive.
According to the press release, the funds raised will be used to expand the R&D center, build a pilot plant, and advance the pipeline under development, as well as to further improve the extrahepatic delivery technology and broaden the application prospects of mRNA dru.
It is worth mentioning that this is the second round of new financing completed within half a year after the company completed the angel round of strategic financing in December 202 Conclusion It is reported that in the just-concluded first quarter, financing events in the pharmaceutical field have been happening continuous.
According to public information, in the first quarter, financing in China's biopharmaceutical field (excluding in vitro diagnostics and testing, e.
) was very active as a whole, with more than 90 Chinese biopharmaceutical companies completing financing of different rounds and natur.
Among them, more than 50 new drug R&D companies have completed early-stage financing (A round/A+ round and befor.
In this regard, analysts said that investment and financing data has a predictive role in the performance of the secondary mark.
From the current point of view, investment opportunities in the field of medicine and health will continue to be optimist.
Among them, new cell therapy, gene therapy, tumor therapy, genetic testing and other fields will still attract the attention of innovative drug compani.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyo.
Since the beginning of this year, the pharmaceutical industry has been setting off a wave of financing; for example, recently, a number of pharmaceutical companies have announced that they will raise or have completed hundreds of millions of financing, which will be used for new drug research and developme.
Kriya Completes $270 Million Series C Financing On May 17, Kriya Therapeutics announced the completion of a $270 million Series C financing round, which will be used to advance its R&D pipeline and further expand its engineering, manufacturing and computing platfor.
It is understood that the company's goal is to become a fully integrated gene therapy company, revolutionizing the design, development and manufacturing of gene therapy, increasing the speed to market and reducing cos.
At present, Kriya has actually built an ecosystem to develop potential "best-in-class" gene therapies, which consists of four core business units, namely technology, manufacturing, research and development, and treatme.
In addition, the company's computational engine, SIRVE, has also been able to integrate the vast amounts of data generated by the company's engineered and high-throughput screening platforms to support machine learning-enabled analysis and intelligent product desi.
Junshi Biology plans to raise 98 billion yuan for innovative drug research and developme.
On May 16, Junshi Biology submitted a prospectus for the issuance of A shares to specific objects in 202 The sponsor is Haitong Securiti.
According to the announcement, the number of shares issued this time does not exceed 70 million shar.
The total amount of funds raised in this issuance (including issuance expenses) shall not exceed RMB 980 billion (including this amoun.
Use raised funds of 6822 billion yuan), including JS001 (PD-1) follow-up domestic and overseas clinical research and development, JS004 (BTLA antibody) domestic and overseas Phase III clinical research and development, JS111 (EGFR exon20) domestic and overseas clinical research and development projects and other early stage projects preclinical studies .
In addition, Junshi Bio also plans to use the raised funds of 298 million yuan to establish a Shanghai headquarters and R&D center in the Shanghai International Medical Park in Shanghai Zhangjiang Science Ci.
Starna Therapeutics completes 150 million yuan in financing and is committed to developing mRNA therapy Recently, Starna Therapeutics announced the completion of 150 million yuan in Series A financi.
This round of financing was led by LYFE Capital (Zhouling Capital), Source Code Capital and Hony Capital And Chunhua Venture Capital followed the investment, Hillhouse Venture Capital and Sherpa Investment continued to increase their investme.
According to the data, Xingrui Medicine was founded in August 2021 and is committed to developing innovative mRNA drugs based on unmet clinical nee.
At present, it has established a technology platform for mRNA design synthesis and lipid nanoparticle (LNP) delivery, which is capable of achieving tissue-specific mRNA drug delive.
According to the press release, the funds raised will be used to expand the R&D center, build a pilot plant, and advance the pipeline under development, as well as to further improve the extrahepatic delivery technology and broaden the application prospects of mRNA dru.
It is worth mentioning that this is the second round of new financing completed within half a year after the company completed the angel round of strategic financing in December 202 Conclusion It is reported that in the just-concluded first quarter, financing events in the pharmaceutical field have been happening continuous.
According to public information, in the first quarter, financing in China's biopharmaceutical field (excluding in vitro diagnostics and testing, e.
) was very active as a whole, with more than 90 Chinese biopharmaceutical companies completing financing of different rounds and natur.
Among them, more than 50 new drug R&D companies have completed early-stage financing (A round/A+ round and befor.
In this regard, analysts said that investment and financing data has a predictive role in the performance of the secondary mark.
From the current point of view, investment opportunities in the field of medicine and health will continue to be optimist.
Among them, new cell therapy, gene therapy, tumor therapy, genetic testing and other fields will still attract the attention of innovative drug compani.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyo.
